Quick Answer
Sarepta Therapeutics, Inc. reported Cash and Equivalents of $801.28 million for fiscal year 2025.
Sarepta Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $801.28M | -27.4% |
| 2024 | $1.10B | +157.5% |
| 2023 | $428.43M | -55.7% |
| 2022 | $966.78M | -54.3% |
| 2021 | $2.12B | +40.8% |
| 2020 | $1.50B | +79.9% |
| 2019 | $835.08M | +125.2% |
| 2018 | $370.83M | -38.2% |
| 2017 | $599.69M | +389.9% |
| 2016 | $122.42M | +52.4% |
| 2015 | $80.30M | +9.2% |
| 2014 | $73.55M | -71.4% |
| 2013 | $256.96M | +36.9% |
| 2012 | $187.66M | +370.3% |
| 2011 | $39.90M | +18.8% |
| 2010 | $33.59M | -30.4% |
| 2009 | $48.27M | +331.3% |
| 2008 | $11.19M | — |
| 1980 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $613.08M | +209.9% | +20.1% |
| June 30, 2025 | $510.60M | +33.1% | +112.0% |
| March 31, 2025 | $240.87M | -43.6% | -78.2% |
| December 31, 2024 | $1.10B | +157.5% | +457.5% |
| September 30, 2024 | $197.85M | -63.5% | -48.4% |
| June 30, 2024 | $383.62M | -55.0% | -10.2% |
| March 31, 2024 | $427.29M | -51.0% | -0.3% |
| December 31, 2023 | $428.43M | -55.7% | -20.9% |
- Sarepta Therapeutics, Inc. showed a decrease of -27.4% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: